Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT) activity is an inborn error of purine metabolism associated with uric acid overproduction and a continuum spectrum of neurological manifestations depending on the degree of the enzymatic deficiency. The prevalence is estimated at 1/380,000 live births in Canada, and 1/235,000 live births in Spain. Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout. Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour. The most severe forms are known as Lesch-Nyhan syndrome (patients are normal at birth and diagnosis can be accomplished when psychomotor delay becomes apparent). Partial HPRT-deficient patients present these symptoms with a different intensity, and in the least severe forms symptoms may be unapparent. Megaloblastic anaemia is also associated with the disease. Inheritance of HPRT deficiency is X-linked recessive, thus males are generally affected and heterozygous female are carriers (usually asymptomatic). Human HPRT is encoded by a single structural gene on the long arm of the X chromosome at Xq26. To date, more than 300 disease-associated mutations in the HPRT1 gene have been identified. The diagnosis is based on clinical and biochemical findings (hyperuricemia and hyperuricosuria associated with psychomotor delay), and enzymatic (HPRT activity determination in haemolysate, intact erythrocytes or fibroblasts) and molecular tests. Molecular diagnosis allows faster and more accurate carrier and prenatal diagnosis. Prenatal diagnosis can be performed with amniotic cells obtained by amniocentesis at about 15-18 weeks' gestation, or chorionic villus cells obtained at about 10-12 weeks' gestation. Uric acid overproduction can be managed by allopurinol treatment. Doses must be carefully adjusted to avoid xanthine lithiasis. The lack of precise understanding of the neurological dysfunction has precluded development of useful therapies. Spasticity, when present, and dystonia can be managed with benzodiazepines and gamma-aminobutyric acid inhibitors such as baclofen. Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended. Self-injurious behaviour must be managed by a combination of physical restraints, behavioural and pharmaceutical treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A familial disorder of uric acid metabolism and central nervous system function
Lesch, M., & Nyhan, W. L. (1964) · The American Journal of Medicine · doi:10.1016/0002-9343(64)90104-4 · Cited by 1,448
Seegmiller, J. E., Rosenbloom, F. M., & Kelley, W. N. (1967) · Science · doi:10.1126/science.155.3770.1682 · Cited by 1,220
A specific enzyme defect in gout associated with overproduction of uric acid.
Kelley, W. N., Rosenbloom, F. M., Henderson, J. F., & Seegmiller, J. E. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.57.6.1735 · Cited by 475
Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency in Gout
KELLEY, W. N., GREENE, M. L., ROSENBLOOM, F. M., HENDERSON, J. F., & SEEGMILLER, J. E. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-1-155 · Cited by 446
Biochemical Evidence of Dysfunction of Brain Neurotransmitters in the Lesch-Nyhan Syndrome
Lloyd, K. G., Hornykiewicz, O., Davidson, L., Shannak, K., Farley, I., Goldstein, M., Shibuya, M., Kelley, W. N., & Fox, I. H. (1981) · New England Journal of Medicine · doi:10.1056/nejm198111053051902 · Cited by 373
Automated DNA sequencing of the human HPRT locus
Edwards, A., Voss, H., Rice, P., Civitello, A., Stegemann, J., Schwager, C., Zimmermann, J., Erfle, H., Caskey, C. T., & Ansorge, W. (1990) · Genomics · doi:10.1016/0888-7543(90)90493-e · Cited by 356
Gibbs, R. A., Nguyen, P.-N., Edwards, A., Civitello, A. B., & Caskey, C. T. (1990) · Genomics · doi:10.1016/0888-7543(90)90545-6 · Cited by 325
Jolly, D. J., Okayama, H., Berg, P., Esty, A. C., Filpula, D., Bohlen, P., Johnson, G. G., Shively, J. E., Hunkapillar, T., & Friedmann, T. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.2.477 · Cited by 324
Hyperuricemia and Gout: Classification, Complications and Management
Boss, G. R., & Seegmiller, J. E. (1979) · New England Journal of Medicine · doi:10.1056/nejm197906283002604 · Cited by 281
Delineation of the motor disorder of Lesch–Nyhan disease
Jinnah, H. A., Visser, J. E., Harris, J. C., Verdu, A., Larovere, L., Ceballos-Picot, I., Gonzalez-Alegre, P., Neychev, V., Torres, R. J., Dulac, O., et al. (2006) · Brain · doi:10.1093/brain/awl056 · Cited by 272
Self-citationRosenbloom, F. M., Henderson, J. F., Caldwell, I. C., Kelley, W. N., & Seegmiller, J. E. (1968) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)56968-x · Cited by 255
Jinnah, H. A., De Gregorio, L., Harris, J. C., Nyhan, W. L., & O’Neill, J. P. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00052-1 · Cited by 248
Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.
Wong, D. F., Harris, J. C., Naidu, S., Yokoi, F., Marenco, S., Dannals, R. F., Ravert, H. T., Yaster, M., Evans, A., Rousset, O., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5539 · Cited by 243
Self‐injurious behavior: Gene–brain–behavior relationships
Schroeder, S. R., Oster‐Granite, M. L., Berkson, G., Bodfish, J. W., Breese, G. R., Cataldo, M. F., Cook, E. H., Crnic, L. S., DeLeon, I., Fisher, W., et al. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/1098-2779(200102)7:1<3::aid-mrdd1002>3.0.co;2-# · Cited by 238
BONE MARROW TRANSPLANTATION IN FIVE CHILDREN WITH SICKLE CELL ANAEMIA
Vermylen, C., Ninane, J., Fernandez Robles, E., & Cornu, G. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92239-8 · Cited by 196
Lesch–Nyhan disease and the basal ganglia
Visser, J. E., Bär, P. R., & Jinnah, H. A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00094-6 · Cited by 195
Presynaptic Dopaminergic Deficits in Lesch–Nyhan Disease
Ernst, M., Zametkin, A. J., Matochik, J. A., Pascualvaca, D., Jons, P. H., Hardy, K., Hankerson, J. G., Doudet, D. J., & Cohen, R. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342403 · Cited by 184
Self-injury in Lesch-Nyhan disease
Anderson, L. T., & Ernst, M. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172213 · Cited by 179
Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease
Jinnah, H. A., Wojcik, B., Hunt, M., Narang, N., Lee, K., Goldstein, M., Wamsley, J. K., Langlais, P. J., & Friedmann, T. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-03-01164.1994 · Cited by 138
Lesch‐Nyhan Disease: Clinical Experience with Nineteen Patients
Christie, R., Bay, C. A., Kaufman, I. A., Bakay, B., Borden, M., & Nyhan, W. L. (1982) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1982.tb13621.x · Cited by 127
Lesch‐nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters
Jankovic, J. J., Caskey, T. C., Stout, J. T., et al. (1988) · Annals of Neurology · doi:10.1002/ana.410230507 · Cited by 122
A molecular survey of hypoxanthine-guanine phosphoribosyltransferase deficiency in man.
Wilson, J. M., Stout, J. T., Palella, T. D., Davidson, B. L., Kelley, W. N., & Caskey, C. T. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112275 · Cited by 112
Taira, T., Kobayashi, T., & Hori, T. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.98.2.0414 · Cited by 100
Davidson, B. L., Tarlé, S. A., Palella, T. D., & Kelley, W. N. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114160 · Cited by 90
HPRT-APRT-deficient mice are not a model for lesch-nyhan syndrome
Engle, S. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.10.1607 · Cited by 81
Silverstein, F. S., Johnston, M. V., Hutchinson, R. J., & Edwards, N. L. (1985) · Neurology · doi:10.1212/wnl.35.6.907 · Cited by 76
A dopamine deficiency model of Lesch-Nyhan disease—the neonatal-6-OHDA-lesioned rat
Breese, G. R., Criswell, H. E., Duncan, G. E., & Mueller, R. A. (1990) · Brain Research Bulletin · doi:10.1016/0361-9230(90)90240-z · Cited by 74
Torres, R. J., Prior, C., & Puig, J. G. (2007) · Metabolism · doi:10.1016/j.metabol.2007.04.013 · Cited by 74
Self-citationA Review of Behavioral Treatments used for Lesch-Nyhan Syndrome
Olson, L., & Houlihan, D. (2000) · Behavior Modification · doi:10.1177/0145445500242003 · Cited by 64
The development of allopurinol.
Rw, R. (1985) · PubMed · Cited by 63
Jinnah, H. A., Jones, M. D., Wojcik, B. E., Rothstein, J. D., Hess, E. J., Friedmann, T., & Breese, G. R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720225.x · Cited by 58
Schretlen, D. J., Harris, J. C., Park, K. S., Jinnah, H. A., & Ojeda, N. (2001) · Journal of the International Neuropsychological Society · doi:10.1017/s135561770177703x · Cited by 56
The Development of Allopurinol
Rundles, R. W. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.1985.00360080174026 · Cited by 55
Xanthine Calculi in the Lesch-Nyhan Syndrome
Brock, W. A., Golden, J. A., & Kaplan, G. W. (1983) · The Journal of Urology · doi:10.1016/s0022-5347(17)51011-3 · Cited by 49
Dopamine Function in Lesch-Nyhan Disease
Nyhan, W. L. (2000) · Environmental Health Perspectives · doi:10.1289/ehp.00108s3409 · Cited by 48
Pralong, É., Pollo, C., Coubes, P. A., Bloch, J., Roulet, É., Tetreault, M. H., Debatisse, D., & Villemure, J. (2005) · Neurophysiologie Clinique · doi:10.1016/j.neucli.2005.12.004 · Cited by 47
Pelled, D., Sperling, O., & Zoref‐Shani, E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721139.x · Cited by 40
A human neuronal tissue culture model for Lesch‐Nyhan disease
Shirley, T. L., Lewers, J. C., Egami, K., Majumdar, A., Kelly, M., Ceballos-Picot, I., Seidman, M. M., & Jinnah, H. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04472.x · Cited by 37
Study of the adenosinergic system in the brain of HPRT knockout mouse (Lesch–Nyhan disease)
Bertelli, M., Cecchin, S., Lapucci, C., Jacomelli, G., Jinnah, H. A., Pandolfo, M., & Micheli, V. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.05.013 · Cited by 34
Molecular, biochemical, and genetic characterization of a female patient with Lesch–Nyhan disease
Rinat, C., Zoref‐Shani, E., Ben‐Neriah, Z., Bromberg, Y., Becker‐Cohen, R., Feinstein, S., Sperling, O., & Frishberg, Y. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2005.09.025 · Cited by 27
Intrastriatal Hypoxanthine Reduces Na+,K+-ATPase Activity and Induces Oxidative Stress in the Rats
Bavaresco, C. S., Chiarani, F., Wannmacher, C. M. D., Netto, C. A., & Wyse, Â. T. D. S. (2007) · Metabolic Brain Disease · doi:10.1007/s11011-006-9037-y · Cited by 26
Pinto, C. S., & Seifert, R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03570.x · Cited by 19
Pinto, C. S., Jinnah, H. A., Shirley, T. L., Nyhan, W. L., & Seifert, R. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03151.x · Cited by 17
Cited by
Richette, P., & Bardin, T. (2010) · The Lancet · doi:10.1016/s0140-6736(09)60883-7 · Cited by 915
Gout: An old disease in new perspective – A review
Ragab, G., Elshahaly, M., & Bardin, T. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.008 · Cited by 599
Matsuo, H., Takada, T., Ichida, K., Nakamura, T., Nakayama, A., Ikebuchi, Y., Ito, K., Kusanagi, Y., Chiba, T., Tadokoro, S., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000237 · Cited by 437
Metadata
- Authors
- Torres, R. J., & Puig, J. G.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2007-12
- Volume
- 2
- Issue
- 1
- Pages
- 48-48
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2108607187
- Cited by
- 307
- References
- 43
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.